Abstract
Introduction: Cervical cancer is the fourth common cancer in women worldwide. In most cases, the disease is induced by persistent high-risk human papillomavirus (HPV) infection. This study aimed to assess the role of cytokeratin 7 (CK7) and cytokeratin 19 (CK19) in HPV-induced cervical epithelial lesions using tissue microarray (TMA). Methods: A retrospective cohort study included females with cervical low-grade intraepithelial lesion (LSIL), high-grade intraepithelial lesion (HSIL), and squamous cell carcinoma (SCC). TMA was constructed using specimens of 270 cases and 233 control tissues. CK7 and CK19 immunohistochemistry was scored as negative or positive. Follow-up information was gathered. Results: CK7 was negative in about 85% of LSILs and positive in 55% of HSILs (p < 0.001). CK19 showed positivity in about 50% of LSILs and 77% of the HSILs (p < 0.001). For cases with available follow-up data, about 69% of CK7-positive LSILs progressed to higher grade lesions and 64% of CK7-positive HSILs showed progression to higher grades (CIN2 to CIN3) or to SCC. Regarding CK19, nearly 66% positive LSILs progressed to HSIL whereas, 62% of positive HSILs showed progression. LSILs with positivity for both markers progressed to HSIL in 70% of cases. Conclusion: CK7 and CK19 positivity are significantly associated with higher grade HPV-induced cervical lesions. Lesions with combined CK7 and CK19 positivity have a higher risk of progression to higher grade lesions.
Journal Section:
Research Article
References
1.
Herrington
C
, Kim
K
, Kong
C
. Tumours of the uterine cervix
. In: WHO classification of tumours editorial board. Female genital tumours. The WHO classification of tumours
. 5th ed. IARC
; 2020
. Vol. 4
; p. 335
–89
.2.
Hashiguchi
M
, Masuda
M
, Kai
K
, Nakao
Y
, Kawaguchi
A
, Yokoyama
M
, et al. Decreased cytokeratin 7 expression correlates with the progression of cervical squamous cell carcinoma and poor patient outcomes
. J Obstet Gynaecol Res
. 2019
;45
(11
):2228
–36
. 3.
Cao
L
, Sun
P-L
, Yao
M
, Chen
S
, Gao
H
. Clinical significance of CK7, HPV-L1, and koilocytosis for patients with cervical low-grade squamous intraepithelial lesions: a retrospective analysis
. Hum Pathol
. 2017
;65
:194
–200
. 4.
Al-Lawati
Z
, Khamis
FA
, Al-Hamdani
A
, Al-Kalbani
M
, Ramadhan
FA
, Al-Rawahi
TR
, et al. Prevalence of human papilloma virus in Oman: genotypes 82 and 68 are dominating
. Int J Infect Dis
. 2020
;93
:22
–7
. 5.
Umphress
B
, Sanchez
B
, Paintal
A
, Nayar
R
, Maniar
KP
. Utility of CK7 versus p16 as a prognostic biomarker in CIN 2
. Am J Surg Pathol
. 2018
;42
(4
):479
–84
. 6.
Mills
A
, Paquette
C
, Terzic
T
, Castle
PE
, Stoler
MH
. CK7 immunohistochemistry as a predictor of CIN1 progression: a retrospective study of patients from the quadrivalent HPV vaccine trials
. Am J Surg Pathol
. 2017
;41
(2
):143
–52
. 7.
Youssef
M
, Canete-Portillo
S
, Yemelyanova
A
, Ronnett
B
. Patterns of cytokeratin 7 expression in cervical squamous intraepithelial lesions
. Am J Clin Pathol
. 2020
;154
(Suppl 1
):S37
. 8.
Smedts
F
, Ramaekers
F
, Link
M
, Lauerova
L
, Troyanovsky
S
, Schijf
C
, et al. Detection of keratin subtypes in routinely processed cervical tissue: implications for tumour classification and the study of cervix cancer aetiology
. Virchows Arch
. 1994
;425
(2
):145
–55
. 9.
Mittal
KR
, Demopoulos
RI
, Goswami
S
. Patterns of keratin 19 expression in normal, metaplastic, condylomatous, atrophic, dysplastic, and malignant cervical squamous epithelium
. Am J Clin Pathol
. 1992
;98
(4
):419
–23
. 10.
Volkova
LV
, Pashov
AI
, Omelchuk
NN
. Cervical carcinoma: oncobiology and biomarkers
. Int J Mol Sci
. 2021
;22
(22
):12571
. 11.
Strojan Fležar
M
, Nedelko
N
, Poljak
M
, Oštrbenk Valenčak
A
, Gutnik
H
. Stratified mucin-producing intraepithelial lesion (SMILE) of the uterine cervix: high-risk HPV genotype predominance and p40 immunophenotype
. Cells
. 2021
;10
(8
):2039
. 12.
He
X
, Wang
Y
, Ping
J
, Xu
W
, Fang
W
, Liu
J
. The serum CK17 and CK19 expressions in cervical cancer patients and their prognostic value
. Am J Transl Res
. 2021
;13
(6
):6439
–45
.13.
Mehrpouya
M
, Pourhashem
Z
, Yardehnavi
N
, Oladnabi
M
. Evaluation of cytokeratin 19 as a prognostic tumoral and metastatic marker with focus on improved detection methods
. J Cell Physiol
. 2019
;234
(12
):21425
–35
. 14.
Wei
XQ
, Ma
Y
, Chen
Y
, Liu
X
, Zhao
M
, Zhou
LW
. Laparoscopic surgery for early cervical squamous cell carcinoma and its effect on the micrometastasis of cancer cells
. Medicine
. 2018
;97
(34
):e11921
. 15.
Samouëlian
V
, Mechtouf
N
, Leblanc
E
, Cardin
GB
, Lhotellier
V
, Querleu
D
, et al. Sensitive molecular detection of small nodal metastasis in uterine cervical cancer using HPV16-E6/CK19/MUC1 cancer biomarkers
. Oncotarget
. 2018
;9
(31
):21641
–54
. 16.
Ren
J
, Zhou
Z-L
, Xu
S
, Yang
Y-J
. Prognostic significance of cytokeratin 19 and squamous cell cancer antigen in histologically negative sentinel lymph nodes of cervical squamous cell carcinoma
. Int J Gynecol Cancer
. 2016
;26
(9
):1679
–85
. 17.
Huang
EC
, Tomic
MM
, Hanamornroongruang
S
, Meserve
EE
, Herfs
M
, Crum
CP
. p16ink4 and cytokeratin 7 immunostaining in predicting HSIL outcome for low-grade squamous intraepithelial lesions: a case series, literature review and commentary
. Mod Pathol
. 2016
;29
(12
):1501
–10
. 18.
Lee
H
, Lee
H
, Cho
YK
. Cytokeratin7 and cytokeratin19 expression in high grade cervical intraepithelial neoplasm and squamous cell carcinoma and their possible association in cervical carcinogenesis
. Diagn Pathol
. 2017
;12
(1
):18
. Erratum in: Diagn Pathol. 2017;12(1):40. 19.
Menz
A
, Bauer
R
, Kluth
M
, Marie von Bargen
C
, Gorbokon
N
, Viehweger
F
, et al. Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors
. Hum Pathol
. 2021
;115
:19
–36
. 20.
Paquette
C
, Mills
AM
, Stoler
MH
. Predictive value of cytokeratin 7 immunohistochemistry in cervical low-grade squamous intraepithelial lesion as a marker for risk of progression to a high-grade lesion
. Am J Surg Pathol
. 2016
;40
(2
):236
–43
. 21.
Arafa
M
, Boniver
J
, Delvenne
P
. Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study
. Appl Immunohistochem Mol Morphol
. 2008
;16
(5
):422
–32
. 22.
Bowden
SJ
, Kalliala
I
, Veroniki
AA
, Arbyn
M
, Mitra
A
, Lathouras
K
, et al. The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: a systematic review and meta-analysis
. EBioMedicine
. 2019
;50
:246
–59
. 23.
Louvanto
K
, Aro
K
, Nedjai
B
, Bützow
R
, Jakobsson
M
, Kalliala
I
, et al. Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia
. Clin Infect Dis
. 2020
;70
(12
):2582
–90
. 24.
Nandakishore Alva
N
, Samyuktha
A
, Shetty
P
, Mysorker
V
. A study of cytokeratin-7 expression and clinicopathological correlation in dysplasia and squamous cell carcinoma of the cervix
. Asian Pac J Cancer Prev
. 2022
;23
(3
):885
–91
. 25.
Chu
P
, Wu
E
, Weiss
LM
. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases
. Mod Pathol
. 2000
;13
(9
):962
–72
. 26.
Liu
L-Z
, Yang
L-X
, Zheng
B-H
, Dong
P-P
, Liu
X-Y
, Wang
Z-C
, et al. CK7/CK19 index: a potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients
. J Surg Oncol
. 2018
;117
(7
):1531
–9
. 27.
Vasilevska
D
, Rudaitis
V
, Lewkowicz
D
, Širvienė
D
, Mickys
U
, Semczuk
M
, et al. Expression patterns of cytokeratins (CK7, CK20, CK19, CK AE1/AE3) in atypical endometrial hyperplasia coexisting with endometrial cancer
. Int J Mol Sci
. 2024
;25
(16
):9084
. 28.
Yan
Q
, Chen
P
, Chen
X
, Chen
G
, Luo
L
, Ruan
P
, et al. Expression of CK7, CK19 and p16 in HPV-mediated oropharyngeal squamous cell carcinoma
. PeerJ
. 2024
;12
:e18286
. 29.
Arafa
M
, Boniver
J
, Delvenne
P
. Progression model tissue microarray (TMA) for the study of uterine carcinomas
. Dis Markers
. 2010
;28
(5
):267
–72
. 30.
Al-Jabri
M
, Al-Badi
S
, Al-Kindi
H
, Arafa
M
. Immunohistochemical expression of BCL-2 in hydatidiform moles: a tissue microarray study
. Pathologica
. 2023
;1
:148
–54
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
